ClinicalTrials.gg
Active, not recruitingNCT07205900Updated Apr 8, 2026

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

A Phase 2 interventional study of HM15275 and Placebo of HM15275 in Obese and Obesity, sponsored by Hanmi Pharmaceutical Company Limited. Active, not recruiting at 14 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.

Read the detailed description

HM-OBCT-201 is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, parallel group study designed to evaluate the efficacy, safety, and tolerability of HM15275 treatment over 36 weeks in obese or overweight adults without Type 2 diabetes mellitus (T2DM).

The study will enroll adult participants with obesity (body mass index [BMI] ≥30 kg/m2 and ≤50 kg/m2) or with overweight (BMI ≥27 kg/m2 and \<30 kg/m2) with at least 1 weight-related comorbidity. Patients with T2DM will be excluded.

Participants in this study will be randomly assigned in a 1:1:1:1:1 ratio to 1 of the 5 treatment arms. Randomization will be stratified by sex (female vs male) and BMI (\<35 vs ≥35 kg/m2).

All participants will undergo a 6-week screening period, a 36-week treatment period (including the dose-titration phase with weekly subcutaneous [SC] injection), and a 4-week safety follow-up period.

02

Conditions studied

  • Obese
  • Obesity

Browse trials for

Keywords

  • Obese
  • Obesity
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 267 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Participant's age at the time of signing the :

    • United States: 18 to 75 years (inclusive)
    • Korea: 19 to 75 years (inclusive)
  2. ≥30 kg/m² and ≤50 kg/m², or ≥27 kg/m² and \<30 kg/m² with ≥1 weight-related comorbidity
  3. Body weight change \<5% over the past 3 months prior to screening
  4. Capable of giving signed informed consent, ability and willingness to comply with all protocol procedures

Key Exclusion Criteria:

  1. Type 1 diabetes mellitus or T2DM, or ≥6.5% / FPG ≥126 mg/dL
  2. Obesity due to endocrine/genetic disorders
  3. Planned or prior obesity surgery (unless >1 year ago for liposuction/abdominoplasty), or device-based obesity therapy (unless removed >6 months ago)
  4. Personal history or current diagnosis of acute or chronic pancreatitis or factors that may increase the risk of pancreatitis, such as a history of cholelithiasis (without cholecystectomy) or alcohol abuse.
  5. Personal or family history of medullary thyroid carcinoma (MTC) or a known genetic condition (e.g., multiple endocrine neoplasia type 2) that predisposes the participant to MTC.
  6. Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
  7. History or current diagnosis of congestive heart failure ( class Ⅲ or Ⅳ), or myocardial infarction, stroke, unstable angina, , or revascularization procedure (e.g., stent or bypass graft surgery) within 3 months prior to screening visit
  8. Personal history or current diagnosis of acute or chronic pancreatitis or factors that may increase the risk of pancreatitis, such as a history of cholelithiasis (without cholecystectomy) or alcohol abuse.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    HM15275

    Participants will receive HM15275 via subcutaneous (SC) injection.

    Drug: HM15275

  • Placebo comparator
    Placebo of HM15275

    Participants will receive placebo of HM15275 via subcutaneous (SC) injection.

    Drug: Placebo of HM15275

Interventions

  • HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.

  • DrugPlacebo of HM15275

    A sterile, matching solution supplied in pre-filled syringes.

06

What researchers measure

Primary outcomes

  1. Percent Change in Body Weight.

    Percent change in body weight from Week 1 to Week 37, measured using a standardized, calibrated scale under fasting conditions.

    Time frame: Up to 41 weeks

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Number of participants with adverse events (AEs) after multiple subcutaneous (SC) doses.

    Time frame: Up to 41 weeks

Other outcomes

  1. Plasma concentration profile

    Plasma concentration profile of HM15275 after multiple subcutaneous (SC) doses.

    Time frame: Up to 41 weeks

07

Study locations

14 sites
  • ProSciento Inc
    Chula Vista, California 91911, United States
  • Accellacare of Duly - Duly Oak Lawn
    Oak Lawn, Illinois 60453, United States
  • Accellacare of McFarland
    Ames, Iowa 50010, United States
  • Accellacare of Cary - Cary Medical Group
    Cary, North Carolina 27511, United States
  • Accellacare of Hickory
    Hickory, North Carolina 28601, United States
  • Raleigh Medical Group, P.A.
    Raleigh, North Carolina 27609, United States
  • Accellacare of Piedmont - Piedmont HealthCare
    Statesville, North Carolina 28626, United States
  • Accellacare of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Accellacare of Winston Salem
    Winston-Salem, North Carolina 27103, United States
  • Accellacare of Charleston
    Mt. Pleasant, South Carolina 29464, United States
  • Accellacare of Bristol-PAC of Tennessee
    Bristol, Tennessee 37620, United States
  • Bristol-Internal Medicine and Pediatric Associates of Bristol, P.C.
    Bristol, Tennessee 37620, United States
  • Texas Clinical Research Institute
    Arlington, Texas 76012, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jan 2027, 13 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 13 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Oct 3, 2025
StartActual
Dec 2, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07205900
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Dec 2, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Apr 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HM15275

Start the discussion